Literature DB >> 27565865

GRK5-Knockout Mice Generated by TALEN-Mediated Gene Targeting.

Tsevelmaa Nanjidsuren1, Chae-Won Park1, Bo-Woong Sim2, Sun-Uk Kim2, Kyu-Tae Chang2, Myung-Hwa Kang3, Kwan-Sik Min1.   

Abstract

Transcription activator-like effector nucleases (TALENs) are a new type of engineered nuclease that is very effective for directed gene disruption in any genome sequence. We investigated the generation of mice with genetic knockout (KO) of the G protein-coupled receptor kinase (GRK) 5 gene by microinjection of TALEN mRNA. TALEN vectors were designed to target exons 1, 3, and 5 of the mouse GRK5 gene. Flow cytometry showed that the activity of the TALEN mRNAs targeted to exons 1, 3, and 5 was 8.7%, 9.7%, and 12.7%, respectively. The TALEN mRNA for exon 5 was injected into the cytoplasm of 180 one-cell embryos. Of the 53 newborns, three (5.6%) were mutant founders (F0) with mutations. Two clones from F028 showed a 45-bp deletion and F039 showed the same biallelic non-frame-shifting 3-bp deletions. Three clones from F041 were shown to possess a combination of frame-shifting 2-bp deletions. All of the mutations were transmitted through the germline but not to all progenies (37.5%, 37.5%, and 57.1% for the F028, F039, and F041 lines, respectively). The homozygote GRK5-KO mice for 28 and 41 lines created on F3 progenies and the homozygous genotype was confirmed by PCR, T7E1 assay and sequencing.

Entities:  

Keywords:  GRK-5; Gene targeting; Knockout; TALEN

Mesh:

Substances:

Year:  2016        PMID: 27565865     DOI: 10.1080/10495398.2016.1176032

Source DB:  PubMed          Journal:  Anim Biotechnol        ISSN: 1049-5398            Impact factor:   2.282


  2 in total

1.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

2.  One-Step Genotyping Method in loxP-Based Conditional Knockout Mice Generated by CRISPR-Cas9 Technology.

Authors:  He Zhu; Siqian Liu; Wenxi He; Fei Sun; Yang Li; Ping Yang; Qilin Yu; Shu Zhang
Journal:  Mol Biotechnol       Date:  2022-05-03       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.